The estimated Net Worth of Ken W. Marshall is at least 7.15 千$ dollars as of 21 November 2018. Mr. Marshall owns over 1,445 units of Aquestive Therapeutics Inc stock worth over 7,153$ and over the last 6 years he sold AQST stock worth over 0$. In addition, he makes 0$ as Senior Vice President - Chief Commercial Officer at Aquestive Therapeutics Inc.
Kenneth has made over 1 trades of the Aquestive Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,445 units of AQST stock worth 14,667$ on 21 November 2018.
The largest trade he's ever made was buying 1,445 units of Aquestive Therapeutics Inc stock on 21 November 2018 worth over 14,667$. On average, Kenneth trades about 161 units every 0 days since 2018. As of 21 November 2018 he still owns at least 1,445 units of Aquestive Therapeutics Inc stock.
You can see the complete history of Mr. Marshall stock trades at the bottom of the page.
Kenneth W. Marshall serves as Senior Vice President - Chief Commercial Officer of the Company. Mr. Marshall joined our Company in January 2018 as our Commercial Leader. Prior to that, Mr. Marshall served as U.S. President and Global Chief Marketing Officer for Aerocrine Inc. In that role, he developed the global marketing strategy and led all aspects of that company’s U.S. business. From 2008 through 2011, Mr. Marshall served as Vice President of Sales and Marketing for Ikaria, Inc., a drug and device company focused on critical care. Mr. Marshall also spent 17 years with GlaxoSmithKline and held several senior positions including Vice President of Marketing for the Neurology, Urology, Lifecycle and HIV business units. Mr. Marshall received his B.S.B.A in Marketing and Economics from Western Carolina University and M.B.A from Houston Baptist University.
Kenneth Marshall is 61, he's been the Senior Vice President - Chief Commercial Officer of Aquestive Therapeutics Inc since 2019. There are 12 older and 9 younger executives at Aquestive Therapeutics Inc. The oldest executive at Aquestive Therapeutics Inc is Gregory Brown, 66, who is the Independent Director.
Ken's mailing address filed with the SEC is C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN, NJ, 07059.
Over the last 6 years, insiders at Aquestive Therapeutics Inc have traded over 1,898,648$ worth of Aquestive Therapeutics Inc stock and bought 370,463 units worth 3,088,399$ . The most active insiders traders include Marco Taglietti、Nancy Lurker、Alexander Mark Schobel. On average, Aquestive Therapeutics Inc executives and independent directors trade stock every 36 days with the average trade being worth of 77,928$. The most recent stock trade was executed by Alexander Mark Schobel on 15 March 2024, trading 50,000 units of AQST stock currently worth 300,000$.
aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.
Aquestive Therapeutics Inc executives and other stock owners filed with the SEC include: